Latest From Alkermes PLC
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.
- Large Molecule
- Nanotechnology, Chips, etc.
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alkermes Inc.
- Western Europe
- Parent & Subsidiaries
- Alkermes PLC
- Senior Management
Richard F Pops, Chmn. & CEO
James M Frates, SVP, CFO
Michael J Landine, SVP, Corp. Dev.
Craig Hopkinson, MD, CMO & SVP, Medicines Dev. & Medical Affairs
Georgianna Harris, PhD, SVP, Reg. Affairs
- Contact Info
Phone: 1 772 8000
1 Burlington Rd.
Dublin 4, MA D04 C5Y6
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.